114 related articles for article (PubMed ID: 17094448)
1. Tracking of green fluorescent protein (GFP)-labeled LAK cells in mice carrying B16 melanoma metastases.
Takashima K; Fujiwara H; Inada S; Atsuji K; Araki Y; Kubota T; Yamagishi H
Anticancer Res; 2006; 26(5A):3327-32. PubMed ID: 17094448
[TBL] [Abstract][Full Text] [Related]
2. [Biodistribution of immune cells in adoptive immunotherapy by using GFP transgenic mice].
Takashima K; Fujiwara H; Kubota K; Inada S; Yoshimura M; Atsuji K; Ueda Y; Yamagishi H
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1847-8. PubMed ID: 15553735
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
[TBL] [Abstract][Full Text] [Related]
4. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
7. Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells.
Nannmark U; Hokland ME; Agger R; Christiansen M; Kjaergaard J; Goldfarb RH; Bagge U; Unger M; Johansson BR; Albertsson PA; Basse PH
In Vivo; 2000; 14(5):651-8. PubMed ID: 11125549
[TBL] [Abstract][Full Text] [Related]
8. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
Basse PH
APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
[TBL] [Abstract][Full Text] [Related]
9. Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells.
Goding S; Yang Q; Mi Z; Robbins PD; Basse PH
Cancer Gene Ther; 2007 May; 14(5):441-50. PubMed ID: 17273184
[TBL] [Abstract][Full Text] [Related]
10. A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin.
Goldfarb RH; Koelemij R; Muirhead KA; Ohlsson-Wilhelm BM; Gray BD; Kuppen PJ; Basse PH; al-Atrash G; Kitson RP
In Vivo; 2000; 14(1):101-4. PubMed ID: 10757065
[TBL] [Abstract][Full Text] [Related]
11. Microvessel origin and distribution in pulmonary metastases of B16 melanoma: implication for adoptive immunotherapy.
Nannmark U; Johansson BR; Bryant JL; Unger ML; Hokland ME; Goldfarb RH; Basse PH
Cancer Res; 1995 Oct; 55(20):4627-32. PubMed ID: 7553640
[TBL] [Abstract][Full Text] [Related]
12. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
[TBL] [Abstract][Full Text] [Related]
13. [Mechanisms of enhanced accumulation of transferred LAK cells into tumor sites after chemotherapy].
Kuramitsu Y
Hokkaido Igaku Zasshi; 1995 May; 70(3):507-17. PubMed ID: 7590601
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of murine melanoma with bryostatin 1.
Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD
Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785
[TBL] [Abstract][Full Text] [Related]
15. Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis.
Amoh Y; Yang M; Li L; Reynoso J; Bouvet M; Moossa AR; Katsuoka K; Hoffman RM
Cancer Res; 2005 Jun; 65(12):5352-7. PubMed ID: 15958583
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle assessment of adoptive transferred lymphokine activated killer cells.
Watanabe R; Tanaka N; Naomoto Y; Moreira LF; Orita K
Jpn J Clin Oncol; 1994 Apr; 24(2):59-65. PubMed ID: 8158860
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide.
Goldfarb RH; Ohashi M; Brunson KW; Kirii Y; Kotera Y; Basse PH; Kitson RP
Anticancer Res; 1998; 18(3A):1441-6. PubMed ID: 9673353
[TBL] [Abstract][Full Text] [Related]
18. Flavone acetic acid enhances accumulation of IL-2 activated NK cells within established metastases.
Kitson RP; Ohashi M; Brunson KW; Goldfarb RH
In Vivo; 1998; 12(6):593-7. PubMed ID: 9891222
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases.
Basse P; Herberman RB; Nannmark U; Johansson BR; Hokland M; Wasserman K; Goldfarb RH
J Exp Med; 1991 Aug; 174(2):479-88. PubMed ID: 1856630
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals.
Kjaergaard J; Hokland ME; Agger R; Skovbo A; Nannmark U; Basse PH
Cancer Immunol Immunother; 2000 Jan; 48(10):550-60. PubMed ID: 10630307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
